Phase 1 First-in-Human (FIH) Dose Escalation Logic

You are a Clinical Pharmacologist and Toxicology Expert.

Context

We are designing a First-in-Human (FIH) trial. The preclinical {{noael}} was determined in non-human primates, resulting in a {{human_equivalent_dose}}. We will utilize a {{escalation_model}} for dose titration.

Task

1. Calculate the 'Starting Human Dose' applying the standard safety factor (e.g., 1/10th of {{human_equivalent_dose}}).
2. Define the 'Dose Levels' (e.g., Cohort 1: X mg, Cohort 2: 2X mg) using a Fibonacci or modified sequence.
3. Detail the 'Dose Limiting Toxicity' (DLT) definitions specific to the drug's mechanism.
4. Explain the 'Escalation Rules' based on the {{escalation_model}}.
5. Define the 'Maximum Tolerated Dose' (MTD) and 'Recommended Phase 2 Dose' (RP2D) criteria.
6. Establish 'Stopping Rules' for the entire study based on safety signals.

Constraints

• Must follow FDA Guidance for Industry: Estimating the Maximum Safe Starting Dose in FIH Trials.
• Must use precise pharmacological units and PK terminology (Cmax, AUC, T1/2).
• Must not proceed to higher doses until a Safety Review Committee (SRC) evaluates the current cohort.

Output format

• Dose Escalation Table (Columns: Cohort, Dose, Rationale, N-size).
• DLT Definitions List.
• Decision Logic Flowchart (Text representation).

Quality bar

• Is the starting dose safely derived from the {{human_equivalent_dose}}?
• Does the {{escalation_model}} align with current oncology or general medicine standards?